MLKL and cancer: The combined release of cDAMPs and iDAMPs during necroptosis not only establishes a proinflammatory milieu but also bridges innate and adaptive immunity, suggesting that necroptosis‐mediated lytic cell death within tumors enhances systemic antitumor immunity.[11] Therefore, understanding the mechanisms by which RIPK3 and MLKL contribute to antitumor responses holds significant potential for immunotherapy across various cancers.